initiation of a new DMARD within 60 days of the discontinuation date of the index biologic; intermittent use of the index biologic--Ն60 days of treatment gap, 'stepdown'--discontinuation of one of the DMARD therapies from the initial combo therapy, 'step-up'--adding a new DMARD for Ն28 consecutive days. Numbers are reported in pairs with ETN first and ADA second. RESULTS: Over the 12-month study period, majority of PsA patients newly initiated ETN/ADA (Nϭ2037/2217) had Ն 1 therapy change (65.3%/69.1% with a median time to change: 113/112 days). Among patients initiated on mono ETN/ADA (Nϭ1410/1496), 40.7%/33.5% patients remained on the index mono therapy, 12.1%/11.6% patients discontinued the treatment, 18.2%/ 14.7% patients had intermittent treatment, 7.0%/11.4% switched to another mono therapy, and 21.9%/29.1% step-up to combo therapy. Among patients initiated on ETN/ ADA in combination with an oral DMARD, 21.4%/26.8% remained on the original combo therapy, 77.5%/72.7% 'stepped down' to a mono therapy, and very few patients discontinued therapy (0.5%/0.1%) or adopting intermittent biologic therapy (0.6%/0.3%). CONCLUSIONS: This study suggests that most of the PsA patients newly initiated on ETN or ADA have a therapy change over the first year. 
PUK2 ISSUES IN THE SYSTEMATIC REVIEW OF DRUGS FOR RARE DISEASES: A CASE STUDY OF ECULIZUMAB FOR AHUS

OBJECTIVES:
Assessing the clinical effectiveness of drugs for rare diseases presents many challenges for systematic reviewers. Atypical haemolytic uraemic syndrome (aHUS) is a rare disease with a worldwide prevalence of between 2.7 and 5.5 per million population. A systematic review was undertaken to assess the clinical effectiveness of eculizumab for the treatment of aHUS. The aim of this research was to highlight issues with applying standard systematic review methods to assess clinical effectiveness where the evidence base is not well developed. METHODS: A systematic review using standard methods was undertaken of eculizumab for the treatment of aHUS. RESULTS: Standard search methods did not identify all relevant information and other sources of evidence were used, such as hand searching and internet searching. Three studies were identified showing eculizumab to be beneficial in treating aHUS. However serious concerns were identified with the evidence base in the review. The issues of concern were: lack of a control group in any of the studies, the use of surrogate outcome measures only, little information available on comparator treatments, lack of clarity on patient selection in the trials and no baseline data available for this patient population. Very little information on eculizumab for aHUS was available in the public domain.
CONCLUSIONS:
The issues highlighted here are of concern in the review of other rare diseases, where information may also be scarce. Guidance is needed on appropriate study designs. There is a need for validated surrogate outcomes and final patient related outcomes, a need for registries of baseline data, long term follow-up data and adverse event information to enable the monitoring of the natural course of the disease. Guidance is need on best practice for the recruitment and selection of patients for trials of treatments for rare diseases. 
PUK3 EVALUATION OF MEDICATION-RELATED PROBLEMS IN HEMODIALYSIS PATIENTS
OBJECTIVES:
To compare health care resource utilization and costs in OAB adults receiving fesoterodine, solifenacin or tolterodine in clinical practice in Spain. METHODS: A retrospective study was designed using primary care electronic medical records from three towns in Spain. Records of patients who initiated OAB therapy between 2008 and 2010 and with a follow-up of at least 52 weeks were retained. Patients over 18 of both genders with an OAB diagnosis [ICD-9-CM 596.51] and a new prescription of fesoterodine, tolterodine or solifenacin were included in the analyses. All type medical visits (primary care, specialist and emergency room), absorbents for urinary incontinence, complementary/diagnostic tests and concomitant medications related with OAB along with cost of antimuscarinics used were analyzed (NHS perspective). Comparisons between antimuscarinics were adjusted by location, age, sex, time since diagnosis, co-morbidity burden and medication possession ratio (medication/time), and were compared using univariate general linear models with bootstrap (1000 re-samples) bias correcting methods to calculate 95% confidence intervals. RESULTS: A total of 1,971 records (58.3% women, 70.1 [SD: 10.6] years) were analyzed; 302 treated with fesoterodine, 952 with solifenacin and 717 with tolterodine. Respectively, 17%, 22% and 25% of subjects used absorbents during the study (pϭ0.014). Adjusted mean health care costs (95% bootstrap CI) were significantly lower with fesoterodine treatment [€1639 (1542; 1725) 
PUK5 EMPLOYMENT RATES AND INDIRECT COSTS IN PATIENTS WITH END-STAGE RENAL DISEASE: DIFFERENCES BETWEEN MODALITIES OF RENAL REPLACEMENT THERAPY
OBJECTIVES:
The present study aims to compare the work status and the indirect costs associated to morbidity in end-stage renal disease patients undergoing one of the following alternatives of renal replacement therapy (RRT): Hemodialysis in a specialized center (HD), automated peritoneal dialysis (APD), continuous ambulatory peritoneal dialysis (CAPD), and renal transplant (TX). METHODS: An analysis on indirect costs from morbidity on RRT was implemented, following the Human Capital Theory. An epidemiological, multicenter, cross-sectional study was conducted. A total of 243 patients in working age were included (32 CAPD, 46 APD, 83 HD and 82 TX). The potentially productive years of life lost (PPYL), the costs of lost labor productivity (LLPc) for the year 2009 and the total cost of PPYL (PPYLtc) until age of retirement were estimated. All the estimations were adjusted by age, sex and different activity rates (obtained from the Spanish National Institute of Statistics). Besides, discount rates of 0%, 3% and 6% were also considered. Chi 2 tests and Kruskal-Wallis or Mann-Whitney U (Bonferroni correction) statistics were used to compare socio-demographic and clinical variables. Due to its skewed distribution, non-parametric analysis (a bootstrap confidence intervals of differences in costs calculated following the simple bias-corrected percentile method -1,000 bootstrap estimates-) was computed to highlight differences in costs. RESULTS: No significant differences were found in age or sex between groups (pϾ0.05). The PPYL were:
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